<DOC>
	<DOCNO>NCT02657005</DOCNO>
	<brief_summary>Ewing sarcoma characterize genomic rearrangement result over-expression ets family transcription factor drive tumor progression . TK216 design inhibit effect inhibit downstream effect EWS-FLI1 transcription factor . This study first human study TK216 subject Ewing sarcoma . The study design establish initial safety efficacy data assess potential TK216 development .</brief_summary>
	<brief_title>TK216 Patients With Relapsed Refractory Ewing Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis Ewing sarcoma ( include ESFT ) subject relapse refractory disease fail standard therapy Symptomatic brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>